---
schema_version: "secwatch.filing_event.v1"
accession: "0001576885-24-000044"
form_type: "8-K"
ticker: "ABOS"
cik: "0001576885"
company_name: "Acumen Pharmaceuticals, Inc."
filed_at: "2024-03-26T23:59:59+00:00"
generated_at: "2026-06-04T07:51:59.565716+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Acumen Pharma FY2023 net loss $52.4M; cash $306.1M; Phase 2 AD trial to start H1 2024

## Summary
- Net loss $52.4M in FY2023 vs $42.9M in 2022; operating loss $61.1M.
- Cash, equivalents and marketable securities $306.1M, sufficient for operations into H1 2027.
- R&D expenses $42.3M (up $9.9M); G&A $18.8M (up $5.9M).
- Plan to initiate Phase 2 ALTITUDE-AD trial of sabirnetug in early AD patients in H1 2024, plus subcutaneous PK study mid-2024.
- Appointed Dr. James Doherty as President and Chief Development Officer in Feb 2024.

## SEC filing metadata
- accession: 0001576885-24-000044
- form_type: 8-K
- ticker: ABOS
- cik: 0001576885
- company_name: Acumen Pharmaceuticals, Inc.
- filed_at: 2024-03-26T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1576885/000157688524000044/0001576885-24-000044-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1576885/000157688524000044/abos-20240326.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001576885-24-000044
- JSON: https://secwatch.observer/filing/0001576885-24-000044.json
- Plain text: https://secwatch.observer/filing/0001576885-24-000044.txt

## Key facts
- Earnings Releases
  Acumen Pharmaceuticals, Inc. reported the year ended December 31, 2023 results: net income $52.4 million.
  - Period: the year ended December 31, 2023
  - Net income: $52.4 million
  - Result: reported results
  source text: Net loss for the year ended December 31, 2023 was $52.4 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/1576885/000157688524000044/0001576885-24-000044-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.